Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes

This study has been terminated.
(Due to potential concerns about liver safety (See Detailed Description))
Information provided by (Responsible Party):
ClinicalTrials.gov Identifier:
First received: November 25, 2011
Last updated: February 24, 2014
Last verified: February 2014

The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).

The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), plus metformin compared to glimepiride plus metformin in participants with type 2 diabetes mellitus (T2DM).

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: TAK-875
Drug: Glimepiride
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination With Metformin in Subjects With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Takeda:

Primary Outcome Measures:
  • Change from Baseline in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline, Week 78 and Week 104. ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.

Secondary Outcome Measures:
  • Incident of Hypoglycemia [ Time Frame: Day 1 to Week 78 and Day 1 to Week 104. ] [ Designated as safety issue: No ]
    The incidence of hypoglycemia (low blood sugar) reported by participants from randomization up to measurement time points.

  • Change from Baseline in body weight [ Time Frame: Baseline, Week 78 and Week 104. ] [ Designated as safety issue: No ]
    The change in body weight collected at each week indicated relative to baseline.

  • Change from Baseline in HbA1c [ Time Frame: Baseline, Week 26 and Week 52. ] [ Designated as safety issue: No ]
    The change in the value of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.

  • Incidence of HbA1c <7% for All Participants [ Time Frame: Week 26, Week 52, Week 78 and Week 104. ] [ Designated as safety issue: No ]
    The incidence of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of less than seven percent for target glycemic control at measurement time points indicated for all participants.

  • Incidence of HbA1c <7% for Participants Who Do Not Report Hypoglycemia [ Time Frame: Week 26, Week 52, Week 78 and Week 104. ] [ Designated as safety issue: No ]
    The incidence of HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) of less than seven percent for target glycemic control at measurement time points indicated for participants who do not report hypoglycemia.

  • Change from Baseline in Fasting Plasma Glucose [ Time Frame: Baseline, Week 26, Week 52, Week 78 and Week 104. ] [ Designated as safety issue: No ]
    The change between the fasting plasma glucose value collected at each week indicated relative to baseline.

Estimated Enrollment: 2610
Study Start Date: January 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAK-875 25 mg QD Drug: TAK-875
TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
Experimental: TAK-875 50 mg QD Drug: TAK-875
TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
Active Comparator: Glimepiride 1-2 mg QD Drug: Glimepiride
Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.

Detailed Description:

Type 2 diabetes mellitus (T2DM) has increased dramatically throughout the world over the past decades despite the availability of several different treatment options. Current pharmacologic treatments include insulin, thiazolidinediones, sulfonylureas, metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) mimetics. A number of these treatments are associated with clinically important side effects such as low blood sugar (hypoglycemia), weight gainflud retention, exaggeration of pre-existent heart failure, and gastrointestinal side effects. These side effects and the disadvantages associated with many of the currently available antidiabetic agents can reduce compliance and limit their long-term use.

Insulin is a hormone that is produced by the body to regulate blood sugar (glucose). In individuals with T2DM, the insulin produced by the body does not effectively control the amount of sugar in the bloodstream. If not properly managed, T2DM may cause elevated blood sugar levels (hyperglycemia) and ultimately result in serious health problems.

In response to this problem, Takeda is developing TAK-875 (an investigational drug) as an addition to diet and exercise to improve blood sugar control in patients with T2DM. TAK-875 may affect the production of insulin and may improve how the body uses the sugar in the blood.

The aim of this study is to find out if TAK-875, when taken for approximately 2 years in combination with current diabetes medicine (called metformin), is safe and effective at helping people with T2DM control their high blood sugar when compared to glimepiride (a type of medication called a sulfonylurea). The study is being done to find out if the combination of TAK-875 plus metformin works as well as the combination of glimepiride plus metformin.

Approximately 2430 patients worldwide aged 18 or over with T2DM, will take part in this study and will be involved in the study for up to 110 or 120 weeks.

TAK-875 is being developed at Takeda Global Research and Development, Inc. as an adjunct to diet and exercise to improve glycemic control in participants with T2DM.

This study will investigate TAK-875 in participants with type 2 diabetes mellitus whose blood sugar level is inadequately controlled with metformin monotherapy.

Due to potential concerns about liver safety, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks.

For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  3. The participant is male or female and 18 years of age or older with a historical diagnosis of T2DM.
  4. The participant meets one of the following criteria:

    1. The participant has an HbA1c level ≥7.0 and <10.0%, and has been on a stable daily dose of ≥1500 mg (or documented MTD) of metformin for at least 2 months prior to Screening. This participant will immediately enter the Placebo Run-in Period, or;
    2. The participant has an HbA1c level ≥ 7.5 and <10.5%, and has been on a stable daily dose of <1500 mg of metformin without documented MTD for at least 2 months prior to Screening. After completing the Screening Visit, this participant will have their metformin dose immediately increased to ≥1500 mg (or MTD) for an 8-week Titration Period. Following this 8-week period, the participant must qualify for entry into the Placebo Run-in Period by completing the Week -3 procedures and having an HbA1c concentration ≥7.0 and <10.0%.
  5. The participant has had no treatment with antidiabetic agents other than metformin within 2 months prior to Screening (Exception: if a participant has received other antidiabetic therapy for ≤7 days within the 2 months prior to Screening).
  6. The participant has a body mass index (BMI) of ≤45 kg/m2 at Screening.
  7. Participants regularly using other, non-excluded medications, must be on a stable dose for at least 4 weeks prior to Screening. However, PRN (as needed) use of prescription or over-the-counter medications is allowed at the discretion of the investigator.
  8. The participant is able and willing to monitor glucose with a home glucose monitor and consistently record his or her own blood glucose concentrations and complete participant diaries.

Additional Inclusion Criteria Prior to Randomization

  1. The participant has an HbA1c concentration ≥7.0% and <10.0%, and a FPG ≤270 mg/dL (15.0 mmol/L) at the Week -1 Visit. (If the subject does not qualify for randomization based on these criteria, the assessment may be repeated weekly, for a maximum of 2 additional weeks).
  2. The participant's compliance with the single-blind study medication during the Placebo Run-in Period is at least 75% and does not exceed 125% based on tablet/capsule counts performed by the study staff.
  3. A female participant of childbearing potential must have a negative urine hCG pregnancy test at Baseline (Day 1) prior to Randomization and prior to administration of the first dose of double-blind study medication.

Exclusion Criteria:

  1. The participant has received any investigational compound within 30 days prior to Screening or has received an investigational antidiabetic drug within the 3 months prior to Screening.
  2. The participant has been randomized into a previous TAK-875 study
  3. The participant is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  4. The participant donated or received any blood products within 12 weeks prior to Screening or is planning to donate blood during the study.
  5. The participant has a hemoglobin ≤12 g/dL (≤120 gm/L) for males and ≤10 g/dL (≤100 gm/L) for females at Screening.
  6. The participant has a systolic blood pressure ≥160 mm Hg or diastolic pressure ≥95 mm Hg at Screening (If the participant meets this exclusion criterion, the assessment may be repeated once at least 30 minutes after the initial measurement).
  7. The participant has history of cancer that has been in remission for <5 years prior to Screening. A history of basal cell carcinoma or stage 1 squamous cell carcinoma of the skin is allowed.
  8. The participant has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >2.0x upper limit of normal (ULN) at Screening.
  9. The participant has a total bilirubin level greater than the ULN at Screening. Exception: if a participant has documented Gilbert's Syndrome the participant will be allowed with an elevated bilirubin level per the investigator's discretion.
  10. The participant has a serum creatinine ≥1.5 mg/dL(males) and ≥1.4 mg/dL(females) and/or estimated glomerular filtration rate (GFR) <60 mL/min/1.73m2 at Screening.
  11. The participant has uncontrolled thyroid disease.
  12. The participant has a history of laser treatment for proliferative diabetic retinopathy within 6 months prior to Screening.
  13. The participant has had gastric banding, or gastric bypass surgery within one year prior to Screening.
  14. The participant has a known history of infection with human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV).
  15. The participant had coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, unstable angina pectoris, clinically significant abnormal electrocardiogram (ECG), cerebrovascular accident or transient ischemic attack within 3 months prior to or at Screening.
  16. The participant has a history of hypersensitivity, allergies, or has had an anaphylactic reaction(s) to any component of TAK-875, metformin, or glimepiride.
  17. The participant has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
  18. The participant received excluded medications prior to Screening or is expected to receive excluded medication.
  19. If female, the participant is pregnant (confirmed by laboratory testing, i.e., serum/urine human chorionic gonadotropin (hCG), in females of childbearing potential) or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  20. The participant is unable to understand verbal or written English or any other language for which a certified translation of the approved informed consent is available.
  21. The participant has any other physical or psychiatric disease or condition that in the judgment of the investigator may affect life expectancy or may make it difficult to successfully manage and follow the participant according to the protocol.

Additional Exclusion Criteria Prior to Randomization

  1. The participant has received excluded medications listed in the protocol during the Placebo Run-in Period (topical and inhaled corticosteroids are allowed).
  2. The participant has a systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥95 mm Hg at Baseline (Day 1) (If the subject meets this exclusion criterion, the assessment may be repeated once at least 30 minutes after the initial measurement and decision will be made based on the second measurement).
  3. The participant has a serum creatinine ≥1.5 mg/dL(≥133µmol/L) [males] and ≥1.4 mg/dL (≥124 µmol/L) [females] and/or estimated glomerular filtration rate (GFR) <60 mL/min/1.73m2 at Visit 3 (Schedule B subjects only).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01481116

  Hide Study Locations
United States, Alabama
Dothan, Alabama, United States
Muscle Shoals, Alabama, United States
United States, Arizona
Goodyear, Arizona, United States
Phoenix, Arizona, United States
Tempe, Arizona, United States
United States, California
Long Beach, California, United States
Mission Hills, California, United States
North Hollywood, California, United States
Norwalk, California, United States
Pismo Beach, California, United States
United States, Florida
Bradenton, Florida, United States
Clearwater, Florida, United States
Coral Gables, Florida, United States
Hialeah, Florida, United States
Orlando, Florida, United States
Pembroke Pines, Florida, United States
United States, Georgia
Decatur, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
LaGrange, Illinois, United States
United States, Indiana
Avon, Indiana, United States
United States, Kansas
Topeka, Kansas, United States
United States, Maryland
Oxon Hill, Maryland, United States
United States, Michigan
Flint, Michigan, United States
United States, Mississippi
Jackson, Mississippi, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Elizabeth, New Jersey, United States
United States, North Carolina
Calabash, North Carolina, United States
Charlotte, North Carolina, United States
Greensboro, North Carolina, United States
Mooresville, North Carolina, United States
Morganton, North Carolina, United States
Raleigh, North Carolina, United States
United States, Ohio
Maumee, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Harleysville, Pennsylvania, United States
Uniontown, Pennsylvania, United States
United States, South Carolina
Greer, South Carolina, United States
Spartanburg, South Carolina, United States
United States, Texas
Dallas, Texas, United States
El Paso, Texas, United States
Ft. Worth, Texas, United States
Houston, Texas, United States
New Braunfels, Texas, United States
San Antonio, Texas, United States
Spring, Texas, United States
Tomball, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Burke, Virginia, United States
Hampton, Virginia, United States
Manassas, Virginia, United States
Ciudad Autonoma de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina
Rosario, Santa Fe, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Cordoba, Argentina
Corrientes, Argentina
Australia, Australian Capital Territory
Canberra, Australian Capital Territory, Australia
Australia, New South Wales
Brookvale, New South Wales, Australia
Mosman, New South Wales, Australia
Woy Woy, New South Wales, Australia
Canberra, Australia
Blagoevgrad, Bulgaria
Gabrovo, Bulgaria
Pleven, Bulgaria
Plovdiv, Bulgaria
Sevlievo, Bulgaria
Sofia, Bulgaria
Stara Zagora, Bulgaria
Varna, Bulgaria
Canada, British Columbia
Victoria, British Columbia, Canada
Canada, Ontario
Oakville, Ontario, Canada
Ottawa, Ontario, Canada
Thornhill, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Laval, Quebec, Canada
Longueuil, Quebec, Canada
Mirabel, Quebec, Canada
Pointe Claire, Quebec, Canada
Ville Saint-Laurent, Quebec, Canada
Bogota, Colombia
Medellin, Colombia
Czech Republic
Benatky nad Jizerou, Czech Republic
Brno, Czech Republic
Ceske Budejovice, Czech Republic
Chocen, Czech Republic
Jindrichuv Hradec, Czech Republic
Marianske Lazne, Czech Republic
Olomouc, Czech Republic
Ostrava, Czech Republic
Ostrava - Moravska Ostrava, Czech Republic
Ostrava - Vitkovice, Czech Republic
Prague 10, Czech Republic
Praha 10, Czech Republic
Praha 4 - Krc, Czech Republic
Praha 5, Czech Republic
Praha 8, Czech Republic
Znojmo, Czech Republic
Paide, Estonia
Rakvere, Estonia
Saku, Estonia
Tallinn, Estonia
Tartu, Estonia
Võru, Estonia
Hong Kong
Hong Kong, Hong Kong
New Territories, Hong Kong
Ashkelon, Israel
Beer Sheva, Israel
Beer Yaakov, Israel
Beer-Sheva, Israel
Givataim, Israel
Hadera, Israel
Haifa, Israel
Holon, Israel
Jerusalem, Israel
Kfar-Saba, Israel
Nahariya, Israel
Petach Tikva, Israel
Petach Tikwa, Israel
Raanana, Israel
Ramat Gan, Israel
Ramat-Gan, Israel
Rechovot, Israel
Rishon le Zion, Israel
Tel Aviv, Israel
Tel-Aviv, Israel
Zefat, Israel
Jelgava, Latvia
Limbazi, Latvia
Ogre, Latvia
Riga, Latvia
Talsi, Latvia
Valmiera, Latvia
Alytus, Lithuania
Kaunas, Lithuania
Klaipeda, Lithuania
Vilnius, Lithuania
Ipoh, Perak, Malaysia
Taiping, Perak, Malaysia
Taiping, Perak, Perak, Malaysia
Petaling Jaya, Selangor, Malaysia
Kuala Lumpur, Malaysia
Melaka, Malaysia
Putrajaya, Malaysia
Terengganu, Malaysia
Mexico, Distrito Federal, Mexico
Cuernavaca, Morelos, Mexico
New Zealand
Auckland, New Zealand
Christchurch, New Zealand
Hamilton, New Zealand
Palmerston North, New Zealand
Rotorua, New Zealand
Tauranga, New Zealand
Wellington, New Zealand
Cebu City, Philippines
Davao City, Philippines
Iloilo City, Philippines
Lipa City, Philippines
Quezon City, Philippines
Tarlac, Philippines
Taytay, Philippines
Bialystok, Poland
Bydgoszcz, Poland
Gdansk, Poland
Grodzisk Mazowiecki, Poland
Kamieniec Zabkowicki, Poland
Katowice, Poland
Leczyca, Poland
Lodz, Poland
Lublin, Poland
Oswiecim, Poland
Parczew, Poland
Plock, Poland
Poznan, Poland
Pulawy, Poland
Ruda Slaska, Poland
Rzeszow, Poland
Sopot, Poland
Torun, Poland
Wroclaw, Poland
Zgierz, Poland
Bacau, Romania
Baia Mare, Romania
Bucuresti, Romania
Constanta, Romania
Iasi, Romania
Oradea, Romania
Ploiesti, Romania
Targu Mures, Romania
Timisoara, Romania
Russian Federation
Kazan, Russian Federation
Kemerovo, Russian Federation
Krasnoyarsk, Russian Federation
Moscow, Russian Federation
Novosibirsk, Russian Federation
St. Petersburg, Russian Federation
Yaroslavl, Russian Federation
South Africa
Port Elizabeth, Eastern Cape, South Africa
Bloemfontein, Free State, South Africa
Johannesburg, Gauteng, South Africa
Kempton Park, Gauteng, South Africa
Krugersdorp, Gauteng, South Africa
Pretoria, Gauteng, South Africa
Durban, KwaZulu-Natal, South Africa
Middelburg, Mpumalanga, South Africa
Cape Town, Western Cape, South Africa
Somerset West, Western Cape, South Africa
Stellenbosch, Western Cape, South Africa
Worcester, Western Cape, South Africa
Chia-Yi City, Taiwan
New Taipei City, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan
Dnipropetrovsk, Ukraine
Ivano-Frankivsk, Ukraine
Kharkiv, Ukraine
Kiev, Ukraine
Kyiv, Ukraine
Lugansk, Ukraine
Lviv, Ukraine
Mykolayiv, Ukraine
Poltava, Ukraine
Ternopil, Ukraine
Vinnytsia, Ukraine
Zaporizhzhia, Ukraine
United Kingdom
Cheadle, Cheshire, United Kingdom
Plymouth, Devon, United Kingdom
Hull, East Riding of Yorkshire, United Kingdom
Bexhill on Sea, East Sussex, United Kingdom
Watford, Hertfordshire, United Kingdom
Thornton-Cleveleys, Lancashire, United Kingdom
Liverpool, Merseyside, United Kingdom
Northwood, Middlesex, United Kingdom
Bath, Somerset, United Kingdom
Swansea, South Glamorgan, United Kingdom
Cardiff, United Kingdom
Sponsors and Collaborators
Study Director: Senior Medical Director Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT01481116     History of Changes
Other Study ID Numbers: TAK-875_304  2011-001731-24  U1111-1124-2296  TAK-875_304CTIL  DOH-27-0512-3913  11-057  NMRR-11-882-10318  HKCTR-1616  262  12/WA/0245 
Study First Received: November 25, 2011
Last Updated: February 24, 2014
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Hong Kong: Department of Health
Taiwan: Department of Health
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: Agência Nacional de Vigilância Sanitária
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Czech: Statni ustav pro kontrolu leciv
Estonia: The State Agency of Medicine
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Israel: Ministry of Health
Latvia: State Agency of Medicines
Lithuania: State Medicine Control Agency - Ministry of Health
Malaysia: National Pharmaceutical Control Bureau
Mexico: Federal Commission for Protection Against Health Risks
New Zealand: Ministry of Health
Philippines: Department of Health
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Romania: National Medicine and Medical Devices Agency
Russia: Ministry of Health of the Russian Federation
South Africa: Medicines Control Council
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Ukraine: The State Expert Center of the Ministry of Ukraine

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Anti-Arrhythmia Agents
Hypoglycemic Agents
Immunologic Factors
Immunosuppressive Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 26, 2016